FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2771800386> ?p ?o ?g. }

• W2771800386 endingPage "115017" @default.
• W2771800386 startingPage "115002" @default.
• W2771800386 abstract "// Anna Palau 1, 2, 6 , Anne-Kathrin Garz 3, 4 , Jeannine Diesch 1 , Anabel Zwick 3 , Roberto Malinverni 1 , Vanesa Valero 1 , Katrina Lappin 5 , Raquel Casquero 1, 2 , Andreas Lennartsson 6 , Johannes Zuber 7 , Tomàs Navarro 1, 8 , Ken I. Mills 5 , Katharina S. Götze 3, 4 and Marcus Buschbeck 1, 2 1 Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain 2 Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain 3 Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany 4 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany 5 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, United Kingdom 6 Current address: Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden 7 Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria 8 Clinical Hematology Department, ICO-Hospital GermansTrias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain Correspondence to: Marcus Buschbeck, email: mbuschbeck@carrerasresearch.org Katharina S. Götze, email: katharina.goetze@tum.de Keywords: myelodysplastic syndromes; polycomb repressive complexes; epigenetic regulation; hematopoietic stem cells; cellular differentiation Received: April 04, 2017     Accepted: November 11, 2017     Published: December 01, 2017 ABSTRACT Genetic lesions affecting epigenetic regulators are frequent in myelodysplastic syndromes (MDS). Polycomb proteins are key epigenetic regulators of differentiation and stemness that act as two multimeric complexes termed polycomb repressive complexes 1 and 2, PRC1 and PRC2, respectively. While components and regulators of PRC2 such as ASXL1 and EZH2 are frequently mutated in MDS and AML, little is known about the role of PRC1. To analyze the role of PRC1, we have taken a functional approach testing PRC1 components in loss- and gain-of-function experiments that we found overexpressed in advanced MDS patients or dynamically expressed during normal hematopoiesis. This approach allowed us to identify the enzymatically active component RING1A as the key PRC1 component in hematopoietic stem cells and MDS. Specifically, we found that RING1A is expressed in CD34 + bone marrow progenitor cells and further overexpressed in high-risk MDS patients. Knockdown of RING1A in an MDS-derived AML cell line facilitated spontaneous and retinoic acid-induced differentiation. Similarly, inactivation of RING1A in primary CD34 + cells augmented erythroid differentiation. Treatment with a small compound RING1 inhibitor reduced the colony forming capacity of CD34 + cells from MDS patients and healthy controls. In MDS patients higher RING1A expression associated with an increased number of dysplastic lineages and blasts. Our data suggests that RING1A is deregulated in MDS and plays a role in the erythroid development defect." @default.
• W2771800386 created "2017-12-22" @default.
• W2771800386 creator A5002606079 @default.
• W2771800386 creator A5011797357 @default.
• W2771800386 creator A5012673928 @default.
• W2771800386 creator A5019299989 @default.
• W2771800386 creator A5023600518 @default.
• W2771800386 creator A5035024964 @default.
• W2771800386 creator A5047653000 @default.
• W2771800386 creator A5049006221 @default.
• W2771800386 creator A5053818250 @default.
• W2771800386 creator A5066615327 @default.
• W2771800386 creator A5070520397 @default.
• W2771800386 creator A5079769684 @default.
• W2771800386 creator A5083923541 @default.
• W2771800386 creator A5091324982 @default.
• W2771800386 date "2017-12-01" @default.
• W2771800386 modified "2023-10-06" @default.
• W2771800386 title "Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes" @default.
• W2771800386 cites W1805136820 @default.
• W2771800386 cites W187238933 @default.
• W2771800386 cites W1949194567 @default.
• W2771800386 cites W1963549191 @default.
• W2771800386 cites W1963736125 @default.
• W2771800386 cites W1971717153 @default.
• W2771800386 cites W1976052439 @default.
• W2771800386 cites W1979882109 @default.
• W2771800386 cites W1981300029 @default.
• W2771800386 cites W1982202983 @default.
• W2771800386 cites W1985587850 @default.
• W2771800386 cites W1993236149 @default.
• W2771800386 cites W2011333145 @default.
• W2771800386 cites W2011753829 @default.
• W2771800386 cites W2014359105 @default.
• W2771800386 cites W2016849135 @default.
• W2771800386 cites W2017625776 @default.
• W2771800386 cites W2021785548 @default.
• W2771800386 cites W2025553576 @default.
• W2771800386 cites W2042563950 @default.
• W2771800386 cites W2070152906 @default.
• W2771800386 cites W2074474322 @default.
• W2771800386 cites W2091077261 @default.
• W2771800386 cites W2098500735 @default.
• W2771800386 cites W2108141473 @default.
• W2771800386 cites W2112802693 @default.
• W2771800386 cites W2114492363 @default.
• W2771800386 cites W2118771330 @default.
• W2771800386 cites W2120997349 @default.
• W2771800386 cites W2127862779 @default.
• W2771800386 cites W2127884678 @default.
• W2771800386 cites W2132236820 @default.
• W2771800386 cites W2146512944 @default.
• W2771800386 cites W2147370638 @default.
• W2771800386 cites W2168534340 @default.
• W2771800386 cites W2170079272 @default.
• W2771800386 cites W2179030599 @default.
• W2771800386 cites W2187478032 @default.
• W2771800386 cites W2202702753 @default.
• W2771800386 cites W2264682687 @default.
• W2771800386 cites W2273962941 @default.
• W2771800386 cites W2279179485 @default.
• W2771800386 cites W2326726820 @default.
• W2771800386 cites W2338415548 @default.
• W2771800386 cites W2339199900 @default.
• W2771800386 cites W2339658711 @default.
• W2771800386 cites W2462184373 @default.
• W2771800386 cites W2531569648 @default.
• W2771800386 cites W2534628206 @default.
• W2771800386 cites W2576960689 @default.
• W2771800386 cites W2585315580 @default.
• W2771800386 doi "https://doi.org/10.18632/oncotarget.22839" @default.
• W2771800386 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5777749" @default.
• W2771800386 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29383137" @default.
• W2771800386 hasPublicationYear "2017" @default.
• W2771800386 type Work @default.
• W2771800386 sameAs 2771800386 @default.
• W2771800386 citedByCount "5" @default.
• W2771800386 countsByYear W27718003862018 @default.
• W2771800386 countsByYear W27718003862020 @default.
• W2771800386 countsByYear W27718003862021 @default.
• W2771800386 countsByYear W27718003862022 @default.
• W2771800386 crossrefType "journal-article" @default.
• W2771800386 hasAuthorship W2771800386A5002606079 @default.
• W2771800386 hasAuthorship W2771800386A5011797357 @default.
• W2771800386 hasAuthorship W2771800386A5012673928 @default.
• W2771800386 hasAuthorship W2771800386A5019299989 @default.
• W2771800386 hasAuthorship W2771800386A5023600518 @default.
• W2771800386 hasAuthorship W2771800386A5035024964 @default.
• W2771800386 hasAuthorship W2771800386A5047653000 @default.
• W2771800386 hasAuthorship W2771800386A5049006221 @default.
• W2771800386 hasAuthorship W2771800386A5053818250 @default.
• W2771800386 hasAuthorship W2771800386A5066615327 @default.
• W2771800386 hasAuthorship W2771800386A5070520397 @default.
• W2771800386 hasAuthorship W2771800386A5079769684 @default.
• W2771800386 hasAuthorship W2771800386A5083923541 @default.
• W2771800386 hasAuthorship W2771800386A5091324982 @default.
• W2771800386 hasBestOaLocation W27718003861 @default.
• W2771800386 hasConcept C104317684 @default.

• next